Bioheart, Inc. , a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, released today preliminary 12 month data from its phase I ANGEL Trial. Fully funded by Bioheart, the trial is being conducted in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute .
http://ift.tt/1saaQ4j
http://ift.tt/1saaQ4j
No comments:
Post a Comment